ネブラスカ州における転移性癌の臨床試験
ネブラスカ州内の拠点で、転移性癌に関する15件の研究が参加者を募集しています。
ネブラスカ州内の都市
公式研究テキスト（英語）
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
- Research Site, Omaha
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07205822Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- University of Nebraska Medical Center, Omaha
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT06943755Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Cancer Partners of Nebraska, Lincoln
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07222800A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Nebraska Cancer Specialists, Omaha
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07277413Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- NHO Revive Research Institute, LLC, Lincoln
- NHO Support Center, Lincoln
- Cancer Partners of Nebraska, Lincoln
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07222566A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- Nebraska Medicine, Omaha
- Nebraska Medicine - Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06989437ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Oncology Hematology West, Pc Dba Nebraska Cancer Specialists, Omaha
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07007559Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Nebraska Cancer Specialists, Omaha
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/02更新 · NCT06072612A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/21更新 · NCT06769698(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
- Nebraska Methodist Hospital, Omaha
被験者募集中第3相
18歳以上 · 全性別 · 2026/06/16更新 · NCT05208047Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
- Nebraska Cancer Specialists (Midwest Cancer Center - Legacy), Omaha
- XCancer Omaha / Urology Cancer Center, Omaha
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/11更新 · NCT05283330Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- Nebraska Cancer Specialists, Omaha
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/02/18更新 · NCT07030257Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
- Nebraska Methodist Hospital, Omaha
被験者募集中第3相
18歳以上 · 全性別 · 2026/02/06更新 · NCT06127407SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Omaha
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
- Nebraska Cancer Specialists (NCS), Omaha
被験者募集中第1相
18歳以上 · 全性別 · 2024/11/07更新 · NCT06190886ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。